Feminine Sexual Dysfunction
Bremelanotide - a first composition in new class medicine named melanocortin receptor agonists under development to address the sexual dysfunction. This new chemical essence is valued in clinical Phase of the test 2 studying efficiency and safe profile of the variable doses this new composition in man, feelling erectile dysfunction (ED.) and women, feelling feminine sexual dysfunction (FSD). The Mechanism of the action bremelanotide can offer the important advantage on currently available product for processing ED. since he acts on pathways, which adjusts the sexual function not acting right in vascular system. The Clinical data indicates that bremelanotide can be efficient on payment of the greater variety patient, sufferring from RED..
“Founded in positive result from experienced safety/clinical pharmacology of the analysis, valuing bremelanotide on patient FSD, Palatin and Pharmaceuticalses of the King is together accepted obligation about passing of the clinical development bremelanotide for FSD and pleased to report the unceasing progress in execution of our program of the development,” said Trevor Hallam, Ph.D., Executive Palatin’s Vice President of the Study & Development. “Both feminine sexual dysfunction and male sexual dysfunction present the significant market possibilities where we believe that bremelanotide has a potential to address unjustified medical need.”
About Feminine Sexual Dysfunction (FSD)
FSD CONSISTS of four components, hypoactive sexual disorder of the desire, feminine sexual disorder of the awakening, dyspareunia or painful intercourse and anorgasmia. To install the diagnosis FSD, these components must be bound personal damage, as defined unnatural woman. February 10, 1999 analysis published in Journal of the American Medical Assotiation, JAMA, named, “Sexual Dysfunction in United Staff: Spreading and Predictors,” indicates that certain form FSD turns out to be will be wide-spread in aproximately 43 percents of the feminine population.
Though the current market ED. - originally served inhibitor PDE-5, which target system, reliable unjustified medical need for alternative sexual dysfunction therapy exists. Much patients contraindicated for, or not-supportive in, inhibitors PDE-5. Besides, the current literature indicates this about one half all patient, which get the initial prescription for inhibitor PDE-5 do not change the prescription exactly on disadvantage side effects basically, questions of the interaction medicine, and/or defect acceptable level to return reaction.
Palatin Technologies, Inc. And King Pharmaceuticals, Inc. declared today that companies have terminated the enrolment in pre-menopausal cohort of the Phase 2 clinical tests valuing bremelanotide in pre- and post-patient menopausal feelling feminine sexual dysfunction (FSD). Clinical test FSD is intended to value the multiple dose to initial safety and efficiency bremelanotide both and post woman menopausal, and will provide the companies by information, which will conduct the choice of the clinical endpoints and values the amount of the effect of the processing for future clinical test. It Is Expected that results thereof test will are released in calendar year 2007. Bremelanotide - a candidate medicine for processing male and feminine sexual dysfunction and works for plenipotentiary approval and commercializations Palatin and Pharmaceuticalses of the King.
